Design Therapeutics logo

Design TherapeuticsNASDAQ: DSGN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

29 March 2021

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$294.43 M
-79%vs. 3y high
59%vs. sector
-vs. 3y high
-vs. sector
-72%vs. 3y high
43%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 20:03:04 GMT
$5.20-$0.04(-0.76%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

DSGN Latest News

Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet
zacks.com21 August 2024 Sentiment: POSITIVE

The consensus price target hints at a 39.7% upside potential for Design Therapeutics (DSGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
globenewswire.com05 August 2024 Sentiment: POSITIVE

Friedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials

Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research18 December 2023 Sentiment: POSITIVE

Design Therapeutics, Inc. (DSGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Why Shares of Design Therapeutics Are Plummeting on Tuesday
The Motley Fool15 August 2023 Sentiment: NEGATIVE

Design focuses on therapies to treat neurological disorders. The company said it has enough cash to fund operations through 2026.

Design Therapeutics stock plunges on trial results for neuromuscular disease treatment
Market Watch15 August 2023 Sentiment: NEGATIVE

Shares of Design Therapeutics Inc. DSGN dropped 45% in premarket trading Tuesday after the biopharma company reported mixed results from an early-stage trial of a treatment for Friedreich ataxia, a genetic neuromuscular disease. The phase 1 trial of the treatment, DT-216, confirmed clinical activity in patients with the disease but also found injection-site reactions, the company said in a release late Monday.

Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
GlobeNewsWire31 May 2023 Sentiment: POSITIVE

CARLSBAD, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported that management will present at the 2023 Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 3:30 p.m. ET in NYC.

Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
GlobeNewsWire24 April 2023 Sentiment: POSITIVE

Treatment with DT-168 Eye Drops Reduced Nuclear Foci and Significantly Improved Mis-Splicing In Vitro Company On-track to Submit Investigational New Drug Application for DT-168 in the Second Half of 2023 CARLSBAD, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that preclinical data for the company's novel GeneTAC™ small molecule, DT-168, an eye drop being developed for the treatment of Fuchs endothelial corneal dystrophy (FECD), will be presented during an oral session at the Association for Research in Vision and Ophthalmology 2023 Annual Meeting (ARVO 2023), which is being held in New Orleans from April 23-27, 2023.

Why Design Therapeutics (DSGN) Stock Is Going Nowhere But Down
InvestorPlace11 April 2023 Sentiment: NEGATIVE

Sorry to be the bearer of bad news, but Design Therapeutics (NASDAQ: DSGN ) has good intentions and less-than-stellar financials. Design Therapeutics may be a pioneer in the field of genomic medicine, and that's commendable.

What type of business is Design Therapeutics?

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

What sector is Design Therapeutics in?

Design Therapeutics is in the Healthcare sector

What industry is Design Therapeutics in?

Design Therapeutics is in the Biotechnology industry

What country is Design Therapeutics from?

Design Therapeutics is headquartered in United States

When did Design Therapeutics go public?

Design Therapeutics initial public offering (IPO) was on 29 March 2021

What is Design Therapeutics website?

https://www.designtx.com

Is Design Therapeutics in the S&P 500?

No, Design Therapeutics is not included in the S&P 500 index

Is Design Therapeutics in the NASDAQ 100?

No, Design Therapeutics is not included in the NASDAQ 100 index

Is Design Therapeutics in the Dow Jones?

No, Design Therapeutics is not included in the Dow Jones index

When was Design Therapeutics the previous earnings report?

No data

When does Design Therapeutics earnings report?

The next expected earnings date for Design Therapeutics is 13 November 2024